Latest Market News

Temas Resources is tapping the Canadian market with a $1.5 million flow-through share placement aimed at advancing its titanium projects in Quebec. The raise supports exploration expenses tied to its proprietary processing technology and resource development.

Fat Prophets Global Contrarian Fund (ASX: FPC) has disclosed the Dividend Reinvestment Plan (DRP) price for its six-month dividend ending December 2025, applying a 2.5% discount to the volume weighted average price, resulting in a DRP price of AUD 1.35 per share.

Asara Resources (ASX:AS1) is pushing ahead at its Kada Gold Project in Guinea’s prolific Siguiri Basin, boasting a 923,000-ounce gold resource and launching expansive 2026 drilling campaigns aimed at significantly growing both Indicated and Inferred categories.

QEM Limited is set to acquire two past-producing critical mineral projects in Idaho, backed by a $2.645 million placement. The move aligns with US efforts to secure domestic supplies of fluorspar, tungsten, and niobium amid global supply chain vulnerabilities.

Ovanti Limited has raised $5.27 million through a discounted placement, aiming to accelerate its global Buy Now Pay Later platform and Super App development with AI integration and merchant expansion.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Omnia Metals has made a decisive entry into the US critical minerals market by acquiring the Stibnite Ridge antimony and silver project and staking the Radix rare earth and gallium project in Montana, backed by a $1.5 million capital raise.

Charger Metals has confirmed significant extensions to spodumene mineralisation at its Medcalf project, with drilling pushing lithium-bearing pegmatites to 600-700m depth and along strike. The company anticipates a substantial resource upgrade following assay results due in the coming weeks.

Australian Unity Office Fund has secured Foreign Investment Review Board approval for the $40 million sale of its Brisbane office tower, setting the stage for a pivotal unitholder meeting to approve the sale, delisting, and wind-up of the fund.

XRF Scientific posted a 13.8% jump in March quarter revenue to $15.8 million, led by strong international sales and new product shipments. The newly operational India office marks a strategic expansion, setting the stage for further growth.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.